Your browser doesn't support javascript.
loading
The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.
Tomita, Yuriko; Takeda, Makoto; Matsuyama, Shutoku.
Afiliação
  • Tomita Y; Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
  • Takeda M; Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
  • Matsuyama S; Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan matuyama@nih.go.jp.
Antimicrob Agents Chemother ; 65(5)2023 05 01.
Article em En | MEDLINE | ID: mdl-33649117
Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article